^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gevokizumab (VPM087)

    i
    Other names: VPM087, XOMA 052, XMA005.2, XOMA 052 Mab, XOMA-052, S-78989, XMA 005.2, XMA 052, S 78989, VPM 087
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    IL-1β inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis. (PubMed, Oncol Lett)
    Most of the adverse reactions were mild and the rate of 3/4 grade TEAE was 10.37% (95% CI, 6.14-14.60%). Gevokizumab was effective and safe in the treatment of patients with advanced dMMR/MSI-H solid tumors and its convenience could significantly improve patient compliance; therefore, the clinical application of envafolimab is promising.
    Retrospective data • Journal • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Enweida (envafolimab) • gevokizumab (VPM087)
    1year
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
    P1, N=168, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jan 2025 --> Oct 2024
    Trial completion date
    |
    CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
    over1year
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
    P1, N=167, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
    over1year
    NSABP FC-12: A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy (clinicaltrials.gov)
    P2; N=31 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Circulating tumor DNA
    |
    Signatera™
    |
    gevokizumab (VPM087)
    almost2years
    NSABP FC-12: A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy (clinicaltrials.gov)
    P2; Not yet recruiting --> Recruiting | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • Enrollment open • Circulating tumor DNA
    |
    Signatera™
    |
    gevokizumab (VPM087)
    almost2years
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
    P1, N=172, Recruiting, Novartis Pharmaceuticals | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Jan 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
    2years
    NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy. (ASCO 2022)
    If ≥9 of 31 pts (29%) are alive and recurrence-free at 12 mos, then gevokizumab will be considered promising for further study. Enrollment continues towards the primary endpoint.
    P2 data • Clinical • Tumor mutational burden • Circulating tumor DNA
    |
    TMB (Tumor Mutational Burden) • IL1B (Interleukin 1, beta)
    |
    Signatera™
    |
    gevokizumab (VPM087)
    2years
    NSABP FC-12: A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy (clinicaltrials.gov)
    P2; Trial completion date: Nov 2025 --> Feb 2026 | Trial primary completion date: Nov 2024 --> Feb 2025
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    Signatera™
    |
    gevokizumab (VPM087)
    over2years
    A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy (clinicaltrials.gov)
    P2; N=31; Not yet recruiting; Sponsor:NSABP Foundation Inc
    New P2 trial • Clinical • Circulating tumor DNA
    |
    Signatera™
    |
    gevokizumab (VPM087)
    over2years
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
    P1, N=172, Recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2024 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Oct 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
    3years
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
    P1, N=172, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jan 2023 --> Jun 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)
    over4years
    Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov)
    P1, N=172, Recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: May 2022 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)